Redeye comments on CTEK’s Q3 report, which showed weaker growth than expected, but this was compensa...
Redeye shares its initial view on Modelon’s Q3 2025 report.
Redeye updates on Better Collective ahead of Q3-results (due 12 November after market close) where w...
Suominen had published some details of its Q3 earnings before the actual release in connection with ...
Redeye reviews BioInvent's Q3 report 2025. The company is doubling down on BI-1206 and BI-1808.
Redeye provides an update following Senzime’s Q3 2025 report.
Fastighetsbolaget Prisma Properties fortsätter att överträffa förväntningarna med en imponerande res...
Redeye presents its preview of RaySearch’s Q3 2025 results due on Friday, November 7.
Redeye presents its preview for Devyser’s Q3 2025 report, due on November 5.
Suominen’s Q3 results were known beforehand since the company released preliminary information about...
Dovre issued another negative profit warning earlier this month and then disclosed Q3 EBIT to be abo...
Suominen Q3 comparable EBITDA of EUR 3.4m and net sales of EUR 100m were pre-announced in connection...
Hanza ökade omsättningen med 27 procent till 1 401 mkr, varav 2 procent organiskt.
* Net sales SEK 529m, +2% vs ABGSCe, +3% vs Factset cons.
Aspo sold its Leipurin segment at a relatively good price in Q3 2025.
Taaleri's Q3 results came in clearly above our expectations on a group level, and performance on the...
* More margin gains, 12% target now looking conservative * Adj.
Vaxxa redovisade totala intäkter på 24,6 MSEK under Q3 2025, en ökning med 14 % mot föregående år.
Marimekko is set to report Q3 figures on Friday, October 31.
Oriola saw solid growth in Q2, and we anticipate a continued good growth pace in Q3.
